Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors

  • Karel Pacak
  • David Taïeb

Part of the Contemporary Endocrinology book series (COE)

Table of contents

  1. Front Matter
    Pages i-xiv
  2. Frediano Inzani, Guido Rindi
    Pages 1-13
  3. Mercedes Robledo, Maria Currás-Freixes, Alberto Cascón
    Pages 15-45
  4. Friedhelm Raue, Karin Frank-Raue
    Pages 65-81
  5. Zhihui Liu, Carol J. Thiele
    Pages 83-125
  6. Samuel Backman, Peyman Björklund
    Pages 127-140
  7. Stephen Walrand, Michel Hesse, Francois Jamar
    Pages 163-200
  8. Uta Eberlein, Michael Lassmann
    Pages 201-217
  9. Susan Richter, Graeme Eisenhofer
    Pages 239-250
  10. David Taïeb, Arthur Varoquaux, Ingo Janssen, Karel Pacak
    Pages 269-294
  11. David Taïeb, Karel Pacak
    Pages 295-319
  12. Alessio Imperiale, Christophe M. Deroose, Elif Hindié, Bernard Goichot
    Pages 321-349
  13. Valentina Ambrosini, Stefano Fanti
    Pages 351-361
  14. Sellam Karunanithi, Ganesh Kumar, Rakesh Kumar
    Pages 363-379
  15. Giorgio Treglia, Arnoldo Piccardo, Luca Giovanella
    Pages 381-399
  16. Janet Pollard, M. Sue O’Dorisio, Thomas O’Dorisio, Yusuf Menda
    Pages 411-427
  17. Sybille Kennel, Ananda Appavoo, Jürgen Schulz, Philippe Barthélémy
    Pages 447-471
  18. Back Matter
    Pages 473-484

About this book


Based on the most novel approaches and cutting-edge clinical and scientific information regarding radionuclide imaging and therapies for neuroendocrine tumors, this clinical guidebook represents a unique collaborative effort between endocrinologists, nuclear physicians, oncologists, surgeons, physicists, radio-pharmacists and geneticists. It begins with the embryology, classification and molecular genetics of gastroenteropancreatic neuroendocrine tumors and carcinoids, chromaffin cell tumors, and MEN1- and MEN2-related tumors. Following a chapter on radiopharmaceuticals in neuroendocrine imaging, it turns to the physics and technology of current and cutting-edge radiology, including SPECT/CT and PET/CT and PET/MR. Discussing of radionuclide imaging covers the tumors mentioned above, as well as pulmonary and thymic neuroendocrine tumors and medullary thyroid carcinoma. A presentation of radionuclide therapies follows, including 131I-MIBG therapy, somatostatin receptor-based therapy, and alpha radionuclide therapy, as well as the role of nanoparticles.

Comprehensive and up-to-date, Diagnostic and Therapeutic Nuclear Medicine for Neuroendocrine Tumors will assist and guide physicians who encounter patients with these conditions, either from a diagnostic or therapeutic standpoint, and particularly emphasizes the current and emerging medical devices and imaging and therapeutic options.


Carcinoid tumor Chromaffin cell tumor Neuroendocrine tumor Radionuclide imaging Radionuclide therapy Pheochromocytoma Paraganglioma MEN1-related tumor MEN2-related tumor Neuroblastoma Gastroenteropancreatic tumor Internal dosimetry Medullary thyroid carcinoma 131I-MIBG therapy Nanoparticles

Editors and affiliations

  • Karel Pacak
    • 1
  • David Taïeb
    • 2
  1. 1.Section on Medical NeuroendocrinologyEunice Kennedy Shriver NICHD, NIHBethesdaUSA
  2. 2.Department of Nuclear MedicineAix-Marseille UniversityMarseilleFrance

Bibliographic information

  • DOI
  • Copyright Information Springer International Publishing Switzerland 2017
  • Publisher Name Humana Press, Cham
  • eBook Packages Medicine
  • Print ISBN 978-3-319-46036-9
  • Online ISBN 978-3-319-46038-3
  • Buy this book on publisher's site
Industry Sectors